Protocol No. A5091043: Phase 3 multi-center, double-blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, on the occurrence of major cardiovascular events in subjects with coronary heart disease or risk equivalents. (ILLUMINATE)
Barter PJ, Caulfield M, Eriksson M, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med. 2007;357:2109-2122.
Link to ClinicalTrials.gov registration: http://clinicaltrials.gov/show/NCT00134264
Pfizer will use reasonable efforts to include accurate and up-to-date information on the ClinicalStudyResults.org web site. However, because the status of studies often changes, Pfizer can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. You agree that access to and use of information posted by Pfizer on the ClinicalStudyResults.org web site is at your own risk. Pfizer disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Pfizer shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Pfizer on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof. The ClinicalStudyResults.org web site is maintained by PhRMA, a trade association of which Pfizer is a member. PhRMA had no role in the sponsorship or conduct of the studies posted by Pfizer on ClinicalStudyResults.org. |
